Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Myocardial perfusion reserve in spared myocardium: correlation with infarct size and left ventricular ejection fraction
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-013-2394-y
PURPOSE: Left ventricular ejection fraction (LVEF) after myocardial infarction is considered to be determined by the size of the infarction and residual function of the spared myocardium. Myocardial perfusion reserve (MPR) has been shown to be a strong prognostic factor in patients with ischaemic heart failure, even stronger than LVEF. In the present study, the interrelationship between MPR, LVEF and infarct size was investigated. METHODS: In total, 102 patients with a prior history of myocardial infarction were included. All underwent rest and stress (13)N-ammonia and gated (18)F-fluorodeoxyglucose ((18)F-FDG)...
Luis Eduardo Juárez-Orozco, Julius Glauche, Erick Alexanderson, Clark J Zeebregts, Hendrikus H Boersma, Andor W J M Glaudemans, Rudi A Dierckx, Dirk J van Veldhuisen, René A Tio, Riemer H J A Slart
Nuclear Medicine Imaging of Infl ammatory Diseases
Published in: Diagnostic Imaging of Infections and Inflammatory Diseases: A Multidisciplinary Approach
Access to document
10.1002/9781118484388.ch17
Inflammatory diseases are often relapsing and require life-long treatment. New specific targeted therapies are being developed, and several clinical trials are being performed to assess the efficacy and safety of this new approach. Nowadays, nuclear medicine techniques greatly contribute to the management and determination of the prognosis of the disease. Most importantly, nuclear medicine techniques are the most sensitive diagnostic modalities for the evaluation of disease activity. This chapter reviews molecular imaging by nuclear medicine techniques, and discusses the clinical problem and methodological considerations. It talks about normal...
Marco Chianelli, Gaurav Malviya, Andor W.J.M. Glaudemans, Alberto Signore
Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-013-2398-7
Purpose Recurrent prostate cancer is usually treated by combining radiotherapy and androgen deprivation therapy. To stage the cancer, choline positron emission tomography (PET)/CT can be performed. It is generally thought that androgen deprivation therapy does not influence choline PET/CT. In this article we focus on the molecular backgrounds of choline and androgens, and the results of preclinical and clinical studies performed using PET/CT. Methods Using PubMed, we looked for the relevant articles about androgen deprivation therapy and choline PET/CT. Results During ADT, a tendency of decreased uptake of...
Utility of F-18-FDG PET(/CT) in patients with systemic and localized amyloidosis
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-013-2375-1
Purpose Amyloidosis is a group of diseases characterized by deposition of fibrils and this deposition may be localized or systemic. The presence of giant cells is typical of localized AL amyloidosis in contrast to systemic amyloidosis. Because of this presence of giant cells we hypothesize that F-18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) may show uptake in localized amyloidosis but not in systemic amyloidosis. The aim of the study was to evaluate the utility of F-18-FDG PET/CT in distinguishing systemic amyloidosis from localized amyloidosis. Methods A retrospective search...
Fluorine-18 labeled fluorodeoxyglucose PET useful for therapy monitoring in localized AL amyloidosis?
Published in: Amyloid: Journal of protein folding disorders
Access to document
10.3109/13506129.2013.773888
Walter Noordzij, Andor W. J. M. Glaudemans, Rudi A. Dierckx, Riemer H. J. A. Slart, Alexander L. Boerboom, Bouke P. C. Hazenberg